What is the recommended treatment for hypertrophic obstructive cardiomyopathy (HOCM)?

Treatment of Hypertrophic Obstructive Cardiomyopathy (HOCM)

For symptomatic HOCM patients with persistent left ventricular outflow tract obstruction (LVOTO) despite initial medical therapy, add either a myosin inhibitor (adults only), disopyramide (with AV nodal blocker), or proceed to septal reduction therapy at an experienced center 1, 2.

Initial Pharmacological Management

Start with beta-blockers or non-dihydropyridine calcium channel blockers (verapamil or diltiazem) as first-line therapy for symptomatic patients with LVOT gradients ≥50 mmHg 1, 2, 3. These agents:

• Lower LVOT gradients through negative inotropic effects
• Beta-blockers specifically alleviate dyspnea and improve quality of life
• Verapamil increases physical resilience
• Common side effects include bradycardia, hypotension, and risk of AV block 3

Escalation for Refractory Symptoms

When first-line therapy fails to control symptoms, the 2024 AHA/ACC guidelines represent a major paradigm shift by elevating myosin inhibitors to Class I recommendation alongside traditional options 1, 2:

Three Class I Options (choose one):

1. Myosin inhibitor (mavacamten) - adult patients only

   • Lowers LVOT gradient and improves quality of life 3
   • Critical caveat: 7-10% risk of reversible LVEF reduction to <50% requiring monitoring 3
   • Absolutely contraindicated in pregnancy due to teratogenic effects 1, 2
   • Must discontinue if LVEF drops below 50% 1, 2

2. Disopyramide - must be combined with AV nodal blocking agent (beta-blocker or calcium channel blocker) to prevent rapid ventricular response

3. Septal reduction therapy (SRT) at experienced centers:

   • Surgical myectomy (gold standard)
   • Alcohol septal ablation (ASA) - less invasive alternative with similar short and long-term outcomes 4
   • Patient selection is crucial; requires multidisciplinary team evaluation 5, 4

Septal Reduction Therapy Selection

Surgical myectomy remains the gold standard for septal reduction, but ASA is a reasonable alternative particularly for:

• Elderly patients
• Those with significant surgical comorbidities
• Patients refusing surgery
• Selected anatomic presentations suitable for ablation 5, 4

Both procedures significantly reduce peak gradients (median reduction to 11.5-24 mmHg post-myectomy) 6.

Critical Management Considerations

Sudden Cardiac Death Risk

For patients with ≥1 major SCD risk factor, discuss estimated 5-year sudden death risk during shared decision-making for ICD placement 1, 2.

Atrial Fibrillation Screening

High-risk patients require extended ambulatory monitoring annually (upgraded to Class I recommendation in 2024) 1, 2. Risk factors include:

• Left atrial dilatation
• Advanced age
• NYHA class III-IV heart failure
• Validated risk scores indicating high AF risk

Lifelong anticoagulation is mandatory after first AF episode 7.

Advanced Heart Failure

If systolic dysfunction develops (LVEF <50%), immediately discontinue cardiac myosin inhibitors 1, 2.

Common Pitfalls to Avoid

1. Do not use vasodilators - they worsen LVOT obstruction
2. Do not use dihydropyridine calcium channel blockers (amlodipine, nifedipine) - only non-dihydropyridines are appropriate
3. Do not give disopyramide without AV nodal blockade - risks tachyarrhythmias
4. Do not continue mavacamten if LVEF falls below 50% - this is a Class I recommendation
5. Do not assume high gradients always mean true obstruction - 22% of post-myectomy patients show elevated gradients without demonstrable LVOT obstruction on 3D imaging 6

Algorithmic Approach

1. Confirm LVOT gradient ≥50 mmHg with symptoms
2. Start beta-blocker OR non-dihydropyridine calcium channel blocker
3. If symptoms persist → Add myosin inhibitor (adults) OR disopyramide (with AV blocker) OR refer for SRT
4. Monitor LVEF if using myosin inhibitor - discontinue if <50%
5. Screen high-risk patients annually for AF with extended monitoring
6. Assess SCD risk and discuss ICD if ≥1 major risk factor present

The 2024 guidelines fundamentally changed HOCM management by adding myosin inhibitors as a Class I option, providing a powerful pharmacological alternative before proceeding to invasive septal reduction 1, 2.